{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:25:48Z","timestamp":1793042748957,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T00:00:00Z","timestamp":1340064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1038\/nrneph.2012.116","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T10:42:53Z","timestamp":1340102573000},"page":"484-490","source":"Crossref","is-referenced-by-count":86,"title":["The role of FGF23 in CKD\u2014with or without Klotho"],"prefix":"10.1038","volume":"8","author":[{"given":"Hirotaka","family":"Komaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,19]]},"reference":[{"key":"BFnrneph2012116_CR1","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh, J.  et al. Prevalence of chronic kidney disease in the United States. JAMA 298, 2038\u20132047 (2007).","journal-title":"JAMA"},{"key":"BFnrneph2012116_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10157-009-0199-x","volume":"13","author":"E Imai","year":"2009","unstructured":"Imai, E.  et al. Prevalence of chronic kidney disease in the Japanese general population. Clin. Exp. Nephrol. 13, 621\u2013630 (2009).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph2012116_CR3","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block, G. A.  et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208\u20132218 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl. 3","key":"BFnrneph2012116_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ndt\/11.supp3.130","volume":"11","author":"E Slatopolsky","year":"1996","unstructured":"Slatopolsky, E. & Delmez, J. A. Pathogenesis of secondary hyperparathyroidism. Nephrol. Dial. Transplant. 11 (Suppl. 3), 130\u2013135 (1996).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ki.2009.466","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba, H. & Fukagawa, M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 77, 292\u2013298 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR6","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.2215\/CJN.02640310","volume":"5","author":"OM Guti\u00e9rrez","year":"2010","unstructured":"Guti\u00e9rrez, O. M. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \u201ctrade-off\u201d hypothesis. Clin. J. Am. Soc. Nephrol. 5, 1710\u20131716 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","volume":"152","author":"BD Parker","year":"2010","unstructured":"Parker, B. D.  et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann. Intern. Med. 152, 640\u2013648 (2010).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2012116_CR8","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","volume":"25","author":"S Seiler","year":"2010","unstructured":"Seiler, S.  et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol. Dial. Transplant. 25, 3983\u20133989 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR9","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova, T.  et al. for the Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432\u20132439 (2011).","journal-title":"JAMA"},{"key":"BFnrneph2012116_CR10","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1681\/ASN.2010121224","volume":"22","author":"J Kendrick","year":"2011","unstructured":"Kendrick, J.  et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 22, 1913\u20131922 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR11","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1681\/ASN.2006080936","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser, D.  et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 18, 2600\u20132608 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2215\/CJN.08070811","volume":"7","author":"RD Semba","year":"2012","unstructured":"Semba, R. D.  et al. Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin. J. Am. Soc. Nephrol. 7, 85\u201391 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2215\/CJN.08680811","volume":"7","author":"C Nakano","year":"2012","unstructured":"Nakano, C.  et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin. J. Am. Soc. Nephrol. 7, 810\u2013819 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez, O. M.  et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584\u2013592 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012116_CR15","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","volume":"24","author":"G Jean","year":"2009","unstructured":"Jean, G.  et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 24, 2792\u20132796 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR16","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1093\/ndt\/gfq191","volume":"25","author":"H Olauson","year":"2010","unstructured":"Olauson, H.  et al. Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol. Dial. Transplant. 25, 3033\u20133038 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR17","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul, C.  et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393\u20134408 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2012116_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","volume":"277","author":"T Yamashita","year":"2000","unstructured":"Yamashita, T., Yoshioka, M. & Itoh, N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277, 494\u2013498 (2000).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrneph2012116_CR19","doi-asserted-by":"crossref","unstructured":"ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26, 345\u2013348 (2000).","DOI":"10.1038\/81664"},{"key":"BFnrneph2012116_CR20","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada, T.  et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl Acad. Sci. USA 98, 6500\u20136505 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph2012116_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bone.2004.04.002","volume":"35","author":"A Benet-Pag\u00e8s","year":"2004","unstructured":"Benet-Pag\u00e8s, A.  et al. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35, 455\u2013462 (2004).","journal-title":"Bone"},{"key":"BFnrneph2012116_CR22","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1210\/jc.2004-0406","volume":"89","author":"Y Takeuchi","year":"2004","unstructured":"Takeuchi, Y.  et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 89, 3979\u20133982 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2012116_CR23","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1210\/jc.2006-2865","volume":"92","author":"A Khosravi","year":"2007","unstructured":"Khosravi, A.  et al. Determination of the elimination half-life of fibroblast growth factor-23. J. Clin. Endocrinol. Metab. 92, 2374\u20132377 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2012116_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada, T.  et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19, 429\u2013435 (2004).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2012116_CR25","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov, I. Z.  et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117, 4003\u20134008 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2012116_CR26","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu, H.  et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J. Biol. Chem. 281, 6120\u20136123 (2006).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2012116_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa, I.  et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770\u2013774 (2006).","journal-title":"Nature"},{"key":"BFnrneph2012116_CR28","doi-asserted-by":"publisher","first-page":"E79","DOI":"10.1152\/ajpendo.90539.2008","volume":"296","author":"X Bai","year":"2009","unstructured":"Bai, X., Dinghong, Q., Miao, D., Goltzman, D. & Karaplis, A. C. Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. Am. J. Physiol. Endocrinol. Metab. 296, E79\u2013E88 (2009).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrneph2012116_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1096\/fj.08-114397","volume":"23","author":"T Nakatani","year":"2009","unstructured":"Nakatani, T.  et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J. 23, 433\u2013441 (2009).","journal-title":"FASEB J."},{"key":"BFnrneph2012116_CR30","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1359\/jbmr.2003.18.7.1227","volume":"18","author":"TJ Weber","year":"2003","unstructured":"Weber, T. J., Liu, S., Indridason, O. S. & Quarles, L. D. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 18, 1227\u20131234 (2003).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2012116_CR31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/jc.2009-1603","volume":"95","author":"T Shimada","year":"2010","unstructured":"Shimada, T.  et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 95, 578\u2013585 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2012116_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin, A.  et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71, 31\u201338 (2007).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.ajkd.2004.04.029","volume":"44","author":"T Shigematsu","year":"2004","unstructured":"Shigematsu, T.  et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 44, 250\u2013256 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012116_CR34","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez, O.  et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16, 2205\u20132215 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR35","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.bone.2009.08.008","volume":"45","author":"RC Pereira","year":"2009","unstructured":"Pereira, R. C.  et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 45, 1161\u20131168 (2009).","journal-title":"Bone"},{"key":"BFnrneph2012116_CR36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/ki.2010.313","volume":"78","author":"H Hasegawa","year":"2010","unstructured":"Hasegawa, H.  et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 78, 975\u2013980 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR37","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova, T.  et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370\u20131378 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR38","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/jc.2004-1039","volume":"90","author":"SL Ferrari","year":"2005","unstructured":"Ferrari, S. L., Bonjour, J. P. & Rizzoli, R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90, 1519\u20131524 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2012116_CR39","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1359\/jbmr.060507","volume":"21","author":"SM Burnett","year":"2006","unstructured":"Burnett, S. M.  et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 21, 1187\u20131196 (2006).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2012116_CR40","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2006-0021","volume":"91","author":"DM Antoniucci","year":"2006","unstructured":"Antoniucci, D. M., Yamashita, T. & Portale, A. A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 91, 3144\u20133149 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2012116_CR41","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1038\/sj.ki.5002000","volume":"70","author":"Y Nishida","year":"2006","unstructured":"Nishida, Y.  et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 70, 2141\u20132147 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00774-007-0779-3","volume":"25","author":"N Ito","year":"2007","unstructured":"Ito, N.  et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J. Bone Miner. Metab. 25, 419\u2013422 (2007).","journal-title":"J. Bone Miner. Metab."},{"key":"BFnrneph2012116_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira, R. B.  et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin. J. Am. Soc. Nephrol. 5, 286\u2013291 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR44","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","volume":"26","author":"E Gonzalez-Parra","year":"2011","unstructured":"Gonzalez-Parra, E.  et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol. Dial. Transplant. 26, 2567\u20132571 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","volume":"59","author":"MI Yilmaz","year":"2012","unstructured":"Yilmaz, M. I.  et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am. J. Kidney Dis. 59, 177\u2013185 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012116_CR46","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/ndt\/gfq419","volume":"26","author":"T Isakova","year":"2011","unstructured":"Isakova, T.  et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol. Dial. Transplant. 26, 584\u2013591 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/sj.ki.5002622","volume":"73","author":"P Urena Torres","year":"2008","unstructured":"Urena Torres, P., Friedlander, G., de Vernejoul, M. C., Silve, C. & Pri\u00e9, D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 73, 102\u2013107 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR48","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/sj.ki.5001788","volume":"70","author":"I Bhan","year":"2006","unstructured":"Bhan, I.  et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int. 70, 1486\u20131494 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR49","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1600-6143.2007.01753.x","volume":"7","author":"P Evenepoel","year":"2007","unstructured":"Evenepoel, P., Naesens, M., Claes, K., Kuypers, D. & Vanrenterghem, Y. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am. J. Transplant. 7, 1193\u20131200 (2007).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph2012116_CR50","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2004070602","volume":"16","author":"B Kestenbaum","year":"2005","unstructured":"Kestenbaum, B.  et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 16, 520\u2013528 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR51","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1053\/j.ajkd.2005.05.025","volume":"46","author":"V Menon","year":"2005","unstructured":"Menon, V.  et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am. J. Kidney Dis. 46, 455\u2013463 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012116_CR52","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1161\/CIRCULATIONAHA.105.553198","volume":"112","author":"M Tonelli","year":"2005","unstructured":"Tonelli, M.  et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112, 2627\u20132633 (2005).","journal-title":"Circulation"},{"key":"BFnrneph2012116_CR53","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1006\/bbrc.2000.4226","volume":"280","author":"N Koh","year":"2001","unstructured":"Koh, N.  et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun. 280, 1015\u20131020 (2001).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrneph2012116_CR54","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/ndt\/gfh827","volume":"20","author":"M Fukagawa","year":"2005","unstructured":"Fukagawa, M. & Kazama, J. J. With or without the kidney: the role of FGF23 in CKD. Nephrol. Dial. Transplant. 20, 1295\u20131298 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR55","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/j.1523-1755.2005.00178.x","volume":"67","author":"JJ Kazama","year":"2005","unstructured":"Kazama, J. J.  et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int. 67, 1120\u20131125 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR56","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/j.1523-1755.2005.00184.x","volume":"67","author":"S Nakanishi","year":"2005","unstructured":"Nakanishi, S.  et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 67, 1171\u20131178 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR57","doi-asserted-by":"publisher","first-page":"c94","DOI":"10.1159\/000086347","volume":"101","author":"H Nishi","year":"2005","unstructured":"Nishi, H.  et al. Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin. Pract. 101, c94\u2013c99 (2005).","journal-title":"Nephron Clin. Pract."},{"key":"BFnrneph2012116_CR58","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ki.2010.352","volume":"79","author":"K Wesseling-Perry","year":"2011","unstructured":"Wesseling-Perry, K.  et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 79, 112\u2013119 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR59","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1093\/ndt\/gfr668","volume":"27","author":"D Hansen","year":"2012","unstructured":"Hansen, D., Rasmussen, K., Pedersen, S. M., Rasmussen, L. M. & Brandi, L. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol. Dial. Transplant. 27, 2263\u20132269 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR60","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2215\/CJN.03630509","volume":"5","author":"JB Wetmore","year":"2010","unstructured":"Wetmore, J. B., Liu, S., Krebill, R., Menard, R. & Quarles, L. D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin. J. Am. Soc. Nephrol. 5, 110\u2013116 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR61","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/ndt\/gfr384","volume":"27","author":"M Koizumi","year":"2012","unstructured":"Koizumi, M., Komaba, H., Nakanishi, S., Fujimori, A. & Fukagawa, M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 27, 784\u2013790 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR62","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0272-6386(04)00817-0","volume":"44","author":"T Sato","year":"2004","unstructured":"Sato, T.  et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am. J. Kidney Dis. 44, 481\u2013487 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012116_CR63","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","volume":"9","author":"F Koiwa","year":"2005","unstructured":"Koiwa, F.  et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther. Apher. Dial. 9, 336\u2013339 (2005).","journal-title":"Ther. Apher. Dial."},{"key":"BFnrneph2012116_CR64","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/ndt\/gfr388","volume":"27","author":"T Shigematsu","year":"2012","unstructured":"Shigematsu, T. & Negi, S. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol. Dial. Transplant. 27, 1050\u20131054 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR65","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000327019","volume":"33","author":"Y Takeda","year":"2011","unstructured":"Takeda, Y.  et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am. J. Nephrol. 33, 421\u2013426 (2011).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2012116_CR66","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J. & Naveh-Many, T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 299, F882\u2013F889 (2010).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2012116_CR67","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/ki.2011.107","volume":"80","author":"I L\u00f3pez","year":"2011","unstructured":"L\u00f3pez, I.  et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 80, 475\u2013482 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR68","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.2005111185","volume":"17","author":"S Liu","year":"2006","unstructured":"Liu, S.  et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17, 1305\u20131315 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR69","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/ki.2009.414","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba, H.  et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 77, 232\u2013238 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR70","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000274483","volume":"31","author":"C Kumata","year":"2010","unstructured":"Kumata, C.  et al. Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am. J. Nephrol. 31, 230\u2013238 (2010).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2012116_CR71","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ki.2009.464","volume":"77","author":"H Galitzer","year":"2010","unstructured":"Galitzer, H., Ben-Dov, I. Z., Silver, J. & Naveh-Many, T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77, 211\u2013218 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR72","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1681\/ASN.2009040427","volume":"21","author":"R Canalejo","year":"2010","unstructured":"Canalejo, R.  et al. FGF23 fails to inhibit uremic parathyroid glands. J. Am. Soc. Nephrol. 21, 1125\u20131135 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR73","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/ki.2010.215","volume":"78","author":"J Hofman-Bang","year":"2010","unstructured":"Hofman-Bang, J., Martuseviciene, G., Santini, M. A., Olgaard, K. & Lewin, E. Increased parathyroid expression of klotho in uremic rats. Kidney Int. 78, 1119\u20131127 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR74","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/ki.2010.501","volume":"79","author":"G Martuseviciene","year":"2011","unstructured":"Martuseviciene, G., Hofman-Bang, J., Clausen, T., Olgaard, K. & Lewin, E. The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium\/potassium-ATPase activity. Kidney Int. 79, 742\u2013748 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2012116_CR75","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1073\/pnas.0902006107","volume":"107","author":"R Goetz","year":"2010","unstructured":"Goetz, R.  et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc. Natl Acad. Sci. USA 107, 407\u2013412 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph2012116_CR76","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1681\/ASN.2008060609","volume":"20","author":"T Isakova","year":"2009","unstructured":"Isakova, T.  et al. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 20, 388\u2013396 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR77","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.1210\/jc.2010-1277","volume":"96","author":"JB Wetmore","year":"2011","unstructured":"Wetmore, J. B.  et al. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J. Clin. Endocrinol. Metab. 96, E57\u2013E64 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2012116_CR78","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1093\/ndt\/gfg451","volume":"18","author":"S Okuno","year":"2003","unstructured":"Okuno, S.  et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 18, 2613\u20132621 (2003).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012116_CR79","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.2215\/CJN.02110310","volume":"5","author":"H Komaba","year":"2010","unstructured":"Komaba, H.  et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 5, 2305\u20132314 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012116_CR80","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng, M.  et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 16, 1115\u20131125 (2005).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.116","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:37:49Z","timestamp":1684456669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,19]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["BFnrneph2012116"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2012.116","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,19]]}}}